Pharmaceutical Research and Manufacturers of America (PhRMA) news and information

The battle continues between drugmakers and healthcare providers over the breadth of the federal 340B drug discount program, which assists providers serving indigent and uninsured patients.
FULL STORY »

Executives at large healthcare associations made healthy financial gains in 2011 as the industry continued to grapple with the transition and uncertainty of health reform.
FULL STORY »

The Pharmaceutical Research and Manufacturers of America named Dr. William Chin executive VP of science and regulatory affairs, effective July 1. Chin, the executive dean for research at Harvard Medical School, will report to PhRMA President and CEO...
FULL STORY »

The head of Europe's medicines regulator is digging in for a fight over data transparency after being stopped from releasing information on drugs from two U.S. companies by a court ruling.
FULL STORY »

Though they are not celebrating in public, executives and lawyers for pharmaceutical companies had to be happy last week after an appeals court in New York concluded that federal law does not prohibit sales reps from marketing drugs for uses not approved by the Food and Drug...
FULL STORY »

Drug and device makers fear the White House's budget-cutting plans will undermine legislation intended to improve the reviews of new products.
FULL STORY »

Virginia became the first state to lob its opposition to healthcare reform in March 2010 when lawmakers declared that no resident would be required to purchase health insurance.
FULL STORY »

Drugmakers were seen as the key group Democrats sought to win over as the White House crafted and pushed through the 2010 healthcare law, according to an investigation by House Republican staff.
FULL STORY »

Among all health industry groups with which the White House was negotiating deals leading up to passage of the 2010 healthcare law, drugmakers were seen by Washington Democrats as the key group, according to a yearlong investigation by House Republican staff.
FULL STORY »

A bill to reauthorize and expand the Food and Drug Administration's user-fee programs easily passed the House of Representatives 387-5.
FULL STORY »